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ABSTRACT
Tumours and immortalized cells avoid telomere
attrition by using either the ribonucleoprotein
enzyme telomerase or a recombination-based alter-
native lengthening of telomeres (ALT) mechanism.
Available evidence from mice suggests that the epi-
genetic state of the telomere may influence the
mechanism of telomere maintenance, but this has
not been directly tested in human cancer. Here we
investigated cytosine methylation directly adjacent
to the telomere as a marker of the telomere’s epi-
genetic state in a panel of human cell lines. We find
that while ALT cells show highly heterogeneous
patterns of subtelomeric methylation, subtelomeric
regions in telomerase-positive cells invariably show
denser methylation than normal cells, being almost
completely methylated. When compared to matched
normal and ALT cells, telomerase-positive cells
also exhibit reduced levels of the telomeric repeat-
containing-RNA (TERRA), whose transcription origi-
nates in the subtelomere. Our results are consistent
with the notion that TERRA may inhibit telomerase:
the heavy cytosine methylation we observe in telo-
merase-positive cells may reflect selection for
TERRA silencing in order to facilitate telomerase
activity at the telomere. These data suggest that
the epigenetic differences between telomerase-
positive and ALT cells may underlie the mechanism
of telomere maintenance in human tumorigenesis
and highlight the broad reaching consequences of
epigenetic dysregulation in cancer.
INTRODUCTION
Critical shortening of telomeric repeats is linked to the
limited capacity for normal human cells to divide and
the subsequent onset of replicative senescence (1,2). The
ability to elongate and maintain telomeres is a key feature
of germline cells, tumours and immortalized cells (3–5). In
around 85% of tumours, telomere length maintenance is
achieved by activation of telomerase (6); telomerase activ-
ity is not detectable or present at very low levels in most
normal human somatic cells (3). About 10–15% of
tumours exhibit telomere stabilization in the absence
of telomerase activity, via the alternative lengthening of
telomeres (ALT) mechanism (7). ALT is a recombination-
based mechanism characterized by telomere length hetero-
geneity (8), and the presence of speciﬁc PML bodies
known as ALT-associated PML bodies (APBs) (9) and
extrachromosomal telomeric repeat DNA (10). It is not
known why some tumours use telomerase and others use
ALT to maintain telomere length.
Telomeres are normally maintained in a hetero-
chromatin-like state, carrying epigenetic modiﬁcations
characteristic of transcriptional repression (11).
Telomeric repeats are associated with histone modiﬁca-
tions typical of heterochromatin and proteins such as
HP1 (12). Methylation of cytosines in CpG dinucleotides
is a well-characterized marker of transcriptional silence;
sequences maintained as heterochromatin, such as retro-
transposons and pericentromeric regions, are usually
heavily methylated (13). Although mammalian telomeric
TTAGGG repeats lack CpG dinucleotides, the immedi-
ately adjacent subtelomeric regions are CpG-rich and in
human somatic cells are methylated (14,15). Subtelomeric
regions also carry repressive histone modiﬁcations
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regions can be considered as epigenetic structures that
are maintained as constitutive heterochromatin (11).
Recent studies in the mouse have suggested that there is
a relationship between the epigenetic state of telomeres
and telomere maintenance. Mice lacking the DNA methyl-
transferase DNMT1 that show dramatic losses of subte-
lomeric DNA methylation display heterogeneous telomere
lengthening reminiscent of that seen in ALT tumours (17).
Although the observed recombination may not have been
telomere speciﬁc, but rather a global consequence of
genome-wide methylation loss, and while the involvement
of telomerase in the telomere lengthening cannot be
excluded (17), these results raise the possibility that the
epigenetic state of the telomere aﬀects telomere length
regulation. More recent evidence from human cancer
cell lines suggests that reduced methylation at a large
subtelomeric CpG-rich repeat is associated with longer
telomeres (18).
We hypothesized that the epigenetic state of the telo-
mere inﬂuences the telomere maintenance mechanism used
in human cancer. By analysing subtelomeric methylation
and telomeric transcription, we ﬁnd that the epigenetic
state of the telomere diﬀers markedly between cells that
use ALT and cells that use telomerase. Unexpectedly, our
results support a model in which telomerase activity,
rather than ALT, is governed by the epigenetic state of
the telomere.
MATERIALS AND METHODS
Human cells, SV40-transformed cells and tumourcell lines
Peripheral blood mononuclear cells (PBMC) were
obtained from adult donors (aged 69, 74, 78 and 81
years) or umbilical cord blood, with informed consent
and the approval of the St. Vincent’s Hospital Human
Research Ethics Committee. All cell lines were grown
in DMEM with 10% fetal bovine serum and penicillin/
streptomycin. Tumour-derived cell lines were derived
from primary human osteosarcomas (143BTK-, SAOS-2,
G292, U2OS, SJSA-1 and MG63) or lung carcinomas
(SK-LU-1 and A2182), and were obtained from the
American Type Culture Collection. SV40-transformed
cells were derived by transfecting ﬁbroblasts from a
single individual with SV40 early region gene constructs,
isolating individual foci of morphologically transformed
cells, and culturing them continuously; cells that became
immortalized were categorized as telomerase-positive
based on a telomerase activity assay (3) or as ALT-
positive based on the absence of telomerase activity and
on the presence of telomere length heterogeneity (19) and
APBs (9) (Bonneﬁn,P., Englezou,A. and Reddel,R.,
unpublished data). Genomic DNA was isolated from
peripheral blood and cultured cells by standard phenol-
chloroform extraction.
In silico analysis of subtelomeric CpG islands
The endmost 2kb of both p and q arms of human
chromosomes, as counted from the proximal end of
the telomeric repeats, was screened for CpG islands
(http://www.urogene.org/methprimer/). Each CpG island
was rated for potential methylation analysis based upon
the availability and uniqueness of sequence, and proximity
to the end of the chromosome. Three regions, on the p
arms of chromosomes 2, 4 and 18, were chosen for anal-
ysis (see Table S1).
Bisulphite allelic sequencing
About 2mg of genomic DNA was subjected to bisulphite
conversion (Epitect, Qiagen). PCR was performed on
100ng bisulphite converted DNA using primers and
parameters as detailed in Table S1. Resultant PCR ampli-
cons were cloned into a plasmid vector and sequenced.
Sequences were excluded from further analysis if they
contained more than one unconverted non-CpG cytosine.
The percentage methylation at each allele was calculated
as the number of methylated CpGs across all sequenced
alleles divided by the total number of CpGs.
Genomic 5-methylcytosine content
The total 5-methylcytosine content of tumour-derived cell
lines was determined by high performance liquid chroma-
tography (HPLC). Genomic DNA (2mg) was digested
with nuclease P1 (Sigma) and calf intestinal phosphatase
(New England Biolabs). HPLC was performed on a
Waters Alliance 2695 with an isocratic elution (2.5–16%
methanol gradient in 50mM phosphate buﬀer, pH 4.5) as
previously described (20).
Quantitation oftelomeric transcript
The telomeric repeat-containing transcript TERRA was
quantitated in normal ﬁbroblasts as well as ALT and tel-
omerase-positive cell lines by slot-blot. A total of 2mg
DNAse-treated total RNA was transferred to a nylon
membrane and probed with oligonucleotides end-labelled
with
32P-g-ATP by T4 polynucleotide kinase (New
England Biolabs) or DNA probes body-labelled with
32P-a-dCTP by random priming (PrimeAGene kit,
Promega). Hybridizations were performed in UltraHyb
or UltraHyb Oligo (Ambion); the membranes were sub-
jected to low-stringency (oligonucleotide probes) or high-
stringency (DNA probes) washes.
Quantitation oftelomeric DNA
Telomeric DNA was quantitated by dot blot. Sheared
genomic DNA (500ng) was transferred to a nylon mem-
brane and probed with a telomeric repeat plasmid body
labelled with
32P-a-dCTP (DECAprime II probe labelling,
Ambion). Hybridization was performed overnight in
Church buﬀer and the membrane subjected to high-strin-
gency washes. After detection, the membrane was stripped
and re-probed with an Alu repeat plasmid, as above.
Statistical analysis
Data were analysed using MedCalc statistical software
version 9.3.8.0 (http://www.medcalc.be/). Student’s t-test
or one-way analysis of variance (ANOVA) with a
Newman–Keuls post hoc test was used to compare aver-
age percent methylation and 5-methylcytosine content
Nucleic Acids Research,2009, Vol.37, No. 4 1153between sample groups. The relationship between global
5-methylcytosine and subtelomeric methylation was ana-
lysed by Spearman’s rank correlation. Average values are
expressed SD. Statistical signiﬁcance was assigned where
P<0.05.
RESULTS AND DISCUSSION
Subtelomeric methylation in normalhuman cells
We ﬁrst sought to determine the normal levels and
patterns of subtelomeric cytosine methylation in human
somatic cells. Subtelomeric methylation has been shown
to be a reliable surrogate marker for the epigenetic state of
the telomere (17); although it is known that human cells
are normally enriched for cytosine methylation at the sub-
telomere (14,15), the extent and patterns of methylation
are not known. We analysed subtelomeric methylation by
choosing CpG islands very close to the telomere (within
2kb), in order to estimate as closely as possible the epige-
netic state of the telomere itself. We identiﬁed subtelo-
meric CpG islands on chromosomes 2p, 4p and 18p
(Figure 1A and Table S1) and analysed their methylation
in peripheral blood mononuclear cells (PBMC) from four
infants (cord blood) and four older adults (69–89 years).
We found them to carry relatively dense cytosine methy-
lation (Figure 1B and Table S2). We observed little
inter-individual variation, with the average percentage
methylation across all loci in all individuals being 81
3%. Every allele examined showed methylation of most
CpGs, with occasional unmethylated CpGs. There was
no diﬀerence between levels of subtelomeric methylation
in young and old individuals (P=0.729). This ﬁnding sug-
gests that the heterochromatic state of human telomeres is
maintained despite the known telomere attrition that
occurs with age, especially in the ﬁrst few years of life
(21). Thus, there may be an important role for telomeric
heterochromatin in the maintenance of telomere function
and integrity, independent of telomere length.
Subtelomeric methylation isheterogeneous in ALT cellsbut
universally increased in telomerase-positive cells
Once we had established the patterns of subtelomeric
methylation in healthy human cells, we compared subte-
lomeric methylation in human tumour-derived cell lines
that use either ALT (n=4) or telomerase (n=4) as the
telomere maintenance mechanism. The ALT tumour cell
lines displayed highly heterogeneous patterns of subtelo-
meric methylation (Figure 2 and Table S2). Individual
subtelomeres showed highly variable methylation, with
some loci displaying dramatically less methylation than
normal PBMC, and others showing more; there was vari-
ation both between loci and between ALT cell lines. One
of the four ALT cell lines (SK-LU-1) did not show a loss
of methylation at any locus examined. In contrast to ALT
cells, telomerase-positive tumour cell lines invariably
showed dense methylation at all subtelomeric loci exam-
ined (971%); nearly all alleles were completely methy-
lated (Figure 2 and Table S2). Telomerase-positive
cells had signiﬁcantly more subtelomeric methylation
than both ALT cells (P=0.013) and normal PBMC
(P<0.001).
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Figure 1. Allelic methylation patterns at human subtelomeric regions in normal cells. (A) Subtelomeric regions of chromosomes 2p and 18p analysed
by bisulphite sequencing. CpGs are represented by small vertical lines and PCR primers by arrows. (B) Bisulphite sequencing maps from normal
human PBMC are shown below the corresponding region in (A). Within each map, horizontal lines show the methylation pattern of individual
alleles: black squares represent methylated CpGs and white squares unmethylated CpGs. The average percent methylation for each individual is
shown at the bottom right of each map. The gap in some alleles is due to a G/A polymorphism/mutation that results in loss of a CpG. C, cord
blood; A, adult.
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malignant cells, and this is commonly reﬂected in altera-
tions of normal patterns of DNA methylation. Tumours
frequently exhibit hypermethylation of gene promoters
that are unmethylated and active in normal tissue (22).
This occurs in the context of a generalized loss of methy-
lation across the genome, predominantly at repetitive ele-
ments (23,24). Therefore, we sought to determine whether
the changes in subtelomeric methylation we observed
in tumour-derived cell lines were reﬂective of global
methylation changes. We measured the percentage of
5-methylcytosine in each ALT and telomerase-positive
tumour cell line using high-performance liquid chroma-
tography (Table 1). We found no relationship between
global methylation levels and either telomere maintenance
mechanism (P=0.844) or the level of subtelomeric
methylation (P=0.922) indicating that the changes in
methylation density we observed at the subtelomere are
independent of the generalized epigenetic dysregulation
characteristic of cancer cells.
To further investigate the association between telomere
maintenance and the epigenetic changes at the subtelo-
mere, and to examine their temporal relationship, we per-
formed bisulphite allelic sequencing on a panel of simian
virus 40 (SV40)-transformed cell lines. These cell lines
were clonally derived and independently immortalized
from the ﬁbroblasts of a single individual; approximately
half of SV40-immortalized ﬁbroblast lines maintain
telomere length via ALT, and the other half activate
telomerase (25). We examined methylation patterns at
the same three subtelomeric loci (2p, 4p and 18p) in
SV40-transformed immortalized clones (three telomer-
ase-positive and three ALT), and compared these with
patterns in pre-immortal SV40-transformed clones with
no detectable telomere maintenance mechanism
(Figure 3). We found that subtelomeric methylation pat-
terns in pre-immortal and immortalized ﬁbroblasts largely
mirrored the patterns we observed in normal PBMC and
tumour-derived cell lines, respectively. Pre-immortal ﬁbro-
blasts demonstrated methylation patterns that were simi-
lar to those seen in normal primary PBMC, with the
exception of one subtelomere in one cell line (JFCF-6/
T.5B at chromosome 2p) which exhibited a considerable
loss of methylation (Figure 3). Subtelomeric methylation
was signiﬁcantly increased in telomerase-positive
SV40-transformed immortalized cells compared with pre-
immortal cells (933% versus 805%, P<0.001;
Figure 3 and Table S3); ALT-positive immortalized
cells showed heterogeneous subtelomeric methylation
between clonal lines and between loci, with average per-
centage methylation ranging from 53% to 91%. The
methylation patterns from pre-immortal cells suggest
that, in general, changes in subtelomeric methylation do
not precede immortalization by a signiﬁcant extent, but
are related to the activation of a telomere maintenance
mechanism. However, our observation of reduced sub-
telomeric methylation at one locus suggests that losses
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Figure 2. Subtelomeric methylation is heterogeneous in tumour-derived ALT cells and increased in telomerase-positive cells. Bisulphite sequencing
maps for subtelomeres at chromosomes 2p, 4p and 18p are shown; those from tumour-derived ALT cells at top and those from tumour-derived
telomerase-positive cells at bottom. Within each map, horizontal lines show the methylation pattern of individual alleles: black squares represent
methylated CpGs and white squares unmethylated CpGs. The average percent methylation for each individual is shown at the bottom right of each
map. The gap in some alleles is due to a G/A polymorphism/mutation that results in loss of a CpG.
Table 1. Total 5-methylcytosine content in telomerase-positive and
ALT tumour-derived cell lines
Cell line 5-methylcytosine
content (%)
a
Telomerase+ 143BTK- 4.100.28
A2182 3.350.08
SJSA-1 3.030.42
MG63 3.990.18
ALT+ SK-LU-1 3.690.08
SAOS-2 3.040.21
G292 4.090.00
U2OS 3.370.24
aExpressed as the percentage of total amount of cytosine SD.
Nucleic Acids Research,2009, Vol.37, No. 4 1155of subtelomeric methylation may occur prior to activation
of telomere maintenance; whether or not this cell line
would be more likely to use ALT if immortalized cannot
be ascertained.
Taken together, our observations in tumour-derived
and SV40-transformed cells indicate that ALT cells can
exhibit stochastic changes in subtelomeric methylation,
whereas telomerase cells consistently show an increase
compared to normal. Recent studies have reported hetero-
geneous telomere lengthening reminiscent of ALT in mice
deﬁcient in the DNA methyltransferase DNMT1 (17).
These mice show drastic reductions in methylation at
four subtelomeric loci as a consequence of their inability
to maintain genomic cytosine methylation. However, the
loss of subtelomeric methylation we observed in ALT does
not occur at all the subtelomeres we examined; in one
ALT cell line (SK-LU-1), we did not observe any loss of
methylation but saw gains of methylation at all three sub-
telomeres. Since methylation patterns do not tend to
change from one cell division to the next, but ALT cells
undergo frequent telomeric recombination (8,26), our
data suggest that recombination occurs at telomeres that
carry heavy subtelomeric methylation. Thus, widespread
loss of subtelomeric methylation does not appear to be
required for ALT. The question remains as to why some
subtelomeric loci in ALT cells showed dramatic losses
of methylation: perhaps they are merely reﬂective of the
stochastic losses of methylation characteristic of tumours
and immortalized cells. This suggestion is supported by
recent data from a panel of human tumour cell lines,
in which losses of methylation at the subtelomeric
D4Z4 repeat correlates with the global reductions in
5-methylcytosine (18).
Our ﬁndings from telomerase-positive cell lines have a
clear implication: the signiﬁcant and consistent increase in
subtelomeric methylation we observe at all loci indicates
that a heterochromatic structure is maintained at telo-
meres in cells that utilize telomerase. This suggests that a
strong selection pressure for telomeric heterochromatin
exists in telomerase-positive cells.
Telomeric transcription is highin ALTcells but lowin
telomerase-positive cells
Heterochromatic states and dense cytosine methylation
are tightly linked to transcriptional repression. Although
it has been assumed that telomeres are transcriptionally
silent, telomeric transcription has recently been described
in mammalian cells (27,28). The telomeric repeat-contain-
ing transcript (TERRA) is transcribed from the C-rich
strand using promoters situated in the subtelomeric
region. Because ALT and telomerase cells exhibit diﬀerent
methylation proﬁles at the subtelomere, we investigated
the levels of TERRA transcripts in ALT and telomerase-
positive cells by RNA slot-blot. Total RNA from each of
the cell lines described above, as well as from primary
human ﬁbroblasts derived from ﬁve individuals, was
hybridized to probes directed against the sense (UUAG
GG) and antisense (CCCUAA) TERRA sequence; signals
were normalized to the signal for GAPDH. We observed
no signiﬁcant signal in any cell line with the CCCUAA
-directed probe (data not shown). The TERRA:GAPDH
ratio was higher in ALT cell lines than in any other
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Figure 3. Subtelomeric methylation in SV40-transformed immortalized cell lines mirrors that of tumour-derived cells. Bisulphite sequencing maps for
subtelomeres at chromosomes 2p, 4p and 18p are shown; those from pre-immortal cells at top, immortalized ALT cells at middle, and immortalized
telomerase-positive cells at bottom. Within each map, horizontal lines show the methylation pattern of individual alleles: black squares represent
methylated CpGs and white squares unmethylated CpGs. The average percent methylation for each individual is shown at the bottom right of each
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much lower TERRA:GAPDH ratio. ALT cells tend to
have longer telomeres than telomerase-positive cells or
normal cells and this could account for their higher
TERRA signal. Therefore to control for telomere length
we measured the amount of telomeric DNA in each
sample (Figure 4B). When corrected for the total
amount of telomeric DNA, tumour-derived ALT cells
still exhibited high TERRA levels compared to tumour-
derived telomerase-positive cells (Figure 4C). The series of
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lized, allowed us to compare TERRA levels in matching
cell types and determine its normal abundance. In this
series, the most striking feature is a dramatic reduction
in TERRA levels in the telomerase-positive immortalized
cells (Figure 4C); normal ﬁbroblasts, SV40 transformed,
non-immortal ﬁbroblasts and immortalized ALT cells all
show comparable levels of TERRA. Taken together, our
data indicate that TERRA transcription is dampened in
telomerase-positive cells, but permitted in ALT cells.
The abundance of TERRA in the two series of cell lines
examined (ﬁbroblasts and tumour-derived cell lines)
appears more closely linked to the mechanism of telomere
maintenance than to the level of subtelomeric methyla-
tion. While telomerase-positive cells, with high levels of
subtelomeric methylation, displayed low levels of
TERRA relative to matched ALT or normal cells, the
SK-LU-1 ALT cell line had a high abundance of
TERRA transcript despite having high subtelomeric
methylation levels. However, we cannot rule out the pos-
sibility that the SK-LU-1 cell line carries losses of methy-
lation at other unexamined subtelomeric loci.
In telomerase-positive cells, low TERRA transcript
levels and high levels of subtelomeric methylation together
indicate that consolidation of telomeric heterochromatin
represses telomeric transcription. In vitro studies suggest
that TERRA transcripts can inhibit the action of telome-
rase, perhaps by blocking the complementary template
region of the RNA component, hTR: when HeLa and
ES cell extracts were incubated with an excess of synthetic
RNA oligonucleotides mimicking TERRA, telomerase
activity was abolished (28). Maintenance of telomeric het-
erochromatin may be necessary in telomerase-positive
cells because the presence of TERRA inhibits telomerase
activity. In cells with signiﬁcant TERRA production, tel-
omerase may be unable to act eﬃciently at the telomere.
Interestingly, TERRA localizes to the telomere (27,28) to
form part of the telomeric chromatin, and so it may inhi-
bit telomerase activity only at the telomeres from which it
is produced. This may explain previous observations of
heterogeneous telomere lengthening in DNMT-deﬁcient
mice with mosaic subtelomeric methylation patterns (17).
Alternatively, it remains a possibility that TERRA pro-
duced from a subset of telomeres may act globally within a
cell to inhibit telomerase activity. Regardless of whether
TERRA acts in situ or in trans to inhibit telomerase, its
existence is closely linked to the mechanism of telomere
maintenance: reduced TERRA levels accompany the pres-
ence of telomerase activity.
Finally, although it has been suggested that the ALT
mechanism of telomere maintenance is facilitated by a loss
of methylation at the subtelomere (17), our data indicate
that a loss of methylation at all subtelomeres is not nec-
essary for ALT. Furthermore, recent ﬁndings from indi-
viduals with ICF syndrome (who lack DNMT3B and
hence the ability to methylate subtelomeric regions) indi-
cate that subtelomeric hypomethylation does not lead to
recombination at the telomere (29). Rather, our results
suggest that it is telomerase activity which is tightly
linked to a change in subtelomeric methylation. It may
be that in ALT cells there is no requirement for the
telomere to be heterochromatic, and telomeres stochasti-
cally lose marks of heterochromatin such as subtelomeric
methylation. Stochastic loss of telomeric heterochromatin
prior to immortalization could increase TERRA produc-
tion and prevent the action of telomerase; although most
such cells would undergo apoptosis at this point, cells that
became immortalized would need to activate an alterna-
tive mechanism of telomere maintenance. In any case, it
appears that consolidation of the heterochromatic state of
all telomeres and reduction of TERRA transcription is a
necessary requirement for telomerase-mediated telomere
lengthening, raising the possibility that there is an under-
lying epigenetic diﬀerence between telomerase-positive
and ALT cells.
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